Acquiring Company
BioGen
Acquired Company
Reata Pharmaceuticals
CambridgePlanoBiotechnologyHealth CareBiotechnology ResearchBiotechnologyHealth CareDescription
Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. As a result of the transaction, Biogen has now acquired SKYCLARYS® (omaveloxolone), as well as other clinical and preclinical pipeline programs.
Quick answer
BioGen is acquiring Reata Pharmaceuticals, announced September 26, 2023. BioGen is based in Cambridge, Massachusetts, United States.
- How much did BioGen pay for Reata Pharmaceuticals?
- The deal value was not disclosed.
- What does BioGen do?
- BioGen is a biotechnology company specializing in the development of therapies for neurological diseases.
- Where are BioGen and Reata Pharmaceuticals based?
- BioGen is based in Cambridge, Massachusetts, United States. Reata Pharmaceuticals is based in Plano, Texas, United States.
- Who are the decision-makers at BioGen?
- Fundz holds 1 contact at BioGen. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Biotechnology Research and Biotechnology
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Versiti Acquires Indianapolis-Based Pearl Pathways (November 7, 2023)
- United Therapeutics To Acquire Miromatrix Medical (October 30, 2023)
- Emmes Acquires Vaxtrials (October 5, 2023)
- Lilly To Acquire Point Biopharma To Expand Oncology Capabilities Into Next-Generation Radioligand Therapies (October 3, 2023)
- Airlife Completes Acquisition Of Avanos Medical’S Respiratory Health Business (October 2, 2023)
- Varian Acquires Aspekt Solutions, Strengthening Advanced Oncology Solutions Offering (September 26, 2023)
Who to call at BioGen, and when
When BioGen changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day BioGen raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BioGen, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BioGen. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BioGen makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Reata Pharmaceuticals?
Reata Pharmaceuticals was acquired by BioGen, based in Cambridge. The deal was reported on September 26, 2023. BioGen is a biotechnology company specializing in the development of therapies for neurological diseases. It has pioneered innovations in treatment for various neurodegenerative conditions. BioGen is publicly traded (BIIB) and operates in Biotechnology.
When did BioGen acquire Reata Pharmaceuticals?
BioGen's acquisition of Reata Pharmaceuticals was reported on September 26, 2023. Biogen Inc. (Nasdaq: BIIB) – has completed the acquisition of Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a company focused on developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Reata Pharmaceuticals do?
Reata is a global biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases with few or no approved therapies. It is privately held, operating in Biotechnology, and is based in Plano.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.